NZ506188A - A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof - Google Patents

A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof

Info

Publication number
NZ506188A
NZ506188A NZ506188A NZ50618899A NZ506188A NZ 506188 A NZ506188 A NZ 506188A NZ 506188 A NZ506188 A NZ 506188A NZ 50618899 A NZ50618899 A NZ 50618899A NZ 506188 A NZ506188 A NZ 506188A
Authority
NZ
New Zealand
Prior art keywords
type
angiotensin
pharmaceutical preparation
receptor agonist
receptor
Prior art date
Application number
NZ506188A
Inventor
Anders Pettersson
Anders Hallberg
Lars Fandriks
Original Assignee
Pharmacore Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacore Ab filed Critical Pharmacore Ab
Publication of NZ506188A publication Critical patent/NZ506188A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Described is a pharmaceutical preparation comprising at least one non-selective angiotensin II type 2 receptor agonist and at least one angiotensin II type 1 receptor antagonist, wherein the angiotensin II type 1 receptor antagonist reduces the negative effects of the non-selective angiotensin II type 2 receptor agonist. The pharmaceutical preparation is useful for the treatment or prophylaxis of a functional disorder of the gastrointestinal tract or multiple organ failure.
NZ506188A 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof NZ506188A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9800550A SE9800550D0 (en) 1998-02-24 1998-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
PCT/SE1999/000262 WO1999043339A1 (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof

Publications (1)

Publication Number Publication Date
NZ506188A true NZ506188A (en) 2003-04-29

Family

ID=20410283

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ506188A NZ506188A (en) 1998-02-24 1999-02-24 A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof

Country Status (18)

Country Link
EP (1) EP1066048A1 (en)
JP (1) JP2002504516A (en)
KR (1) KR20010041211A (en)
CN (1) CN1291104A (en)
AU (1) AU755949B2 (en)
BR (1) BR9908188A (en)
CA (1) CA2319123A1 (en)
EE (1) EE200000481A (en)
HU (1) HUP0101411A3 (en)
ID (1) ID26639A (en)
IL (1) IL137990A0 (en)
IS (1) IS5594A (en)
MX (1) MXPA00008172A (en)
NO (1) NO20004215L (en)
NZ (1) NZ506188A (en)
SE (1) SE9800550D0 (en)
SK (1) SK11522000A3 (en)
WO (1) WO1999043339A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1793101A (en) * 1999-12-16 2001-06-25 University Of Southern California Methods for treating and preventing damage to mucosal tissue
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
DK1395566T3 (en) 2001-05-31 2008-01-07 Vicore Pharma Ab Tricyclic compounds useful as angiotensin II agonists
ES2384450T3 (en) 2005-04-12 2012-07-05 Vicore Pharma Ab NEW AGONISTS OF ANGIOTENSIN II TRICLIQUE.
CA2603254C (en) 2005-04-12 2013-10-29 Vicore Pharma Ab New bicyclic angiotensin ii agonists
JP5202301B2 (en) 2005-04-12 2013-06-05 ヴィコール・ファルマ・アーベー Novel tricyclic angiotensin II agonist
SG170116A1 (en) * 2005-12-14 2011-04-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
US20150119329A1 (en) * 2012-04-16 2015-04-30 New York University Modulation of angiotensin ii receptors for the prevention and treatment of malaria cerebral
CN107405406A (en) 2015-03-02 2017-11-28 维科尔药物公司 For treating the angiotensin-ii receptor activator of pulmonary fibrosis
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
EP4007592A1 (en) 2019-08-02 2022-06-08 LanthioPep B.V. Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
GB201913603D0 (en) 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
KR20230004501A (en) 2020-03-19 2023-01-06 바이코어 파마 아베 New Compounds Useful for the Treatment and/or Prevention of Diseases, Disorders, or Conditions Associated with Angiotensin II
GB202004094D0 (en) 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202006074D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006079D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202006081D0 (en) 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
GB202013721D0 (en) 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
GB202104038D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
EP4313953A1 (en) 2021-03-23 2024-02-07 Vicore Pharma AB Selective angiotensin ii receptor ligands
GB202104033D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
AU2022306778A1 (en) 2021-07-09 2024-01-18 Vicore Pharma Ab New selective angiotensin ii compounds
GB202115303D0 (en) 2021-10-25 2021-12-08 Vicore Pharma Ab New formulation
KR20240148359A (en) 2022-02-10 2024-10-11 바이코어 파마 아베 Use of buloxibutide for the treatment of idiopathic pulmonary fibrosis
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use
TW202404959A (en) 2022-04-06 2024-02-01 大陸商武漢人福創新藥物研發中心有限公司 At2r agonist
WO2024133942A1 (en) 2022-12-22 2024-06-27 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease
WO2024149712A1 (en) 2023-01-09 2024-07-18 Vicore Pharma Ab Selective angiotensin ii compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444067A (en) * 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
AU3708295A (en) * 1994-11-04 1996-05-31 Stefan L. Marklund Use of receptor agonists to stimulate superoxide dismutase activity
SE9501881D0 (en) * 1995-05-19 1995-05-19 Astra Ab New pharmacological use of AII receptor antagonists
US5834432A (en) * 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
SE9502219D0 (en) * 1995-06-19 1995-06-19 Astra Ab Novel medical use

Also Published As

Publication number Publication date
BR9908188A (en) 2000-10-24
SK11522000A3 (en) 2001-04-09
HUP0101411A3 (en) 2002-11-28
JP2002504516A (en) 2002-02-12
WO1999043339A1 (en) 1999-09-02
MXPA00008172A (en) 2002-06-21
SE9800550D0 (en) 1998-02-24
AU755949B2 (en) 2003-01-02
EP1066048A1 (en) 2001-01-10
NO20004215D0 (en) 2000-08-23
IS5594A (en) 2000-08-21
CN1291104A (en) 2001-04-11
CA2319123A1 (en) 1999-09-02
NO20004215L (en) 2000-09-18
HUP0101411A2 (en) 2002-03-28
AU2753799A (en) 1999-09-15
EE200000481A (en) 2002-02-15
IL137990A0 (en) 2001-10-31
ID26639A (en) 2001-01-25
KR20010041211A (en) 2001-05-15

Similar Documents

Publication Publication Date Title
NZ506188A (en) A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
BR9910180A (en) Pharmaceutical composition, processes for the treatment of a condition associated with reduced nicotine transmission, for the identification of a positive modulator of a nicotinic receptor agonist and for the identification of a compound, compound, and use of a positive modulator of a nicotinic receptor agonist
NO20004581L (en) Preventive or therapeutic agent for inflammatory disease comprising IL-6 antagonist
CA2259148A1 (en) Solid oral dosage forms of valsartan
ES2181055T3 (en) GALENIC FORMULATIONS CONTAINING OPTIACE ANTAGONISTS.
YU39400A (en) Opioid agonist/antagonist combinations
CA2427815A1 (en) Controlled release hydrocodone formulations
EP1762236A3 (en) Formulations of alpha adrenergic receptor antagonists and their uses
WO1995031985A3 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
MX9505065A (en) Orally used pharmaceutical composition,.
MX9505064A (en) Orally used pharmaceutical composition,.
TR199900651T2 (en) Kaplanm�� par�ac�k form�lasyonu.
AU1667500A (en) N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
ATE266420T1 (en) COMBINATION PREPARATION CONTAINING SELECTIVE NMDA NR2B ANTAGONISTS AND COX-2 INHIBITORS
NZ502495A (en) Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome
PT1146872E (en) UTILIZATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS FOR TREATMENT OF MYOCARDIAL ACUTE FIST.
BG106031A (en) Prucalopride oral solution
NO943070D0 (en) antitussives
BR9909529A (en) Paroxetine maleate
WO2003020315A1 (en) Medicinal compositions containing angiotensin ii receptor antagonist
EA200401617A1 (en) COMBINATION OF NMDA ANTAGONIST AND ACETYL CHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALCHEIMER'S Disease
AP2004003054A0 (en) Combination of selective PDE4 inhibitor and an adrenergic beta-2 receptor agonist
BR9712628A (en) Derivatives of 8 (9) -dehydroestradiol
AU2003202455A1 (en) A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
MX9710002A (en) Novel medical use.

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: PHARMACORE AB, SE

Free format text: OLD OWNER(S): A+ SCIENCE INVEST AB

RENW Renewal (renewal fees accepted)
PSEA Patent sealed